- Home
- PENG vs NVAX Comparison
PENG vs NVAX Comparison
Compare PENG & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | NVAX |
|---|---|---|
| Founded | 1988 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | PENG | NVAX |
|---|---|---|
| Price | $22.01 | $6.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 9 |
| Target Price | ★ $27.50 | $10.78 |
| AVG Volume (30 Days) | 1.2M | ★ 3.9M |
| Earning Date | 01-07-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.28 | ★ 2.07 |
| Revenue | ★ $1,368,794,000.00 | $1,064,651,000.00 |
| Revenue This Year | $8.56 | $58.91 |
| Revenue Next Year | $15.95 | N/A |
| P/E Ratio | $77.07 | ★ $3.34 |
| Revenue Growth | 16.91 | ★ 20.27 |
| 52 Week Low | $14.20 | $5.01 |
| 52 Week High | $29.80 | $11.55 |
Technical Indicators
Market Signals| Indicator | PENG | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 41.68 |
| Support Level | $19.63 | $6.56 |
| Resistance Level | $22.08 | $7.03 |
| Average True Range (ATR) | 0.82 | 0.25 |
| MACD | 0.50 | 0.08 |
| Stochastic Oscillator | 96.71 | 64.67 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.